Lumida
/IDYA
⌘K
IDEAYA Biosciences Inc

IDEAYA Biosciences Inc

IDYA
$37.59USD+0.37%+0.14 today

MARKET CAP

3.6B

P/E (TTM)

FWD P/E

DAY RANGE

$37 – $38

52W RANGE

$24
$43

AI Summary

Stalk
StalkMedium

IDYA has printed a Bullish Exhaustion candle at recent highs amid extreme overbought conditions, signaling waning upside momentum. Despite a Stage 2 advancing structure with price above rising EMAs and an uptrend, short-term weakness into the 9/21 EMA zone deters immediate entry. Medium-term bias remains bullish, but deferred pullbacks into the rising EMA support zone should be monitored for acceptance before engaging.

  • Phase 2/3 darovasertib + crizotinib trial achieved 6.9-month median PFS
  • Generated $8.9M in Q2 collaboration revenue
  • Reported Q2 net loss of $112.5M, wider than Q1
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$27.9M$50.9M$23.4M$7.0M$218.7M
YoY %+43.0%+82.3%-54.1%-70.1%+3024.4%
P / Sales29.8x14.1x86.6x299.9x14.0x
EV / Sales29.4x13.6x81.1x297.1x13.9x
Gross Profit, Adj.$27.9M$50.9M$23.4M$7.0M$218.7M
YoY %+43.0%+82.3%-54.1%-70.1%+3024.4%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit29.4x13.6x81.1x297.1x13.9x
EBITDA, Adj.$-47.2M$-60.4M$-132.0M$-324.6M$-156.6M
YoY %-39.1%-27.9%-118.5%-146.0%+51.8%
Margin %-169.1%-118.6%-564.3%-4637.0%-71.6%
EV / EBITDA-17.4x-11.4x-14.4x-6.4x-19.4x
EBIT$-50.3M$-62.5M$-134.4M$-327.0M$-159.3M
YoY %-42.2%-24.3%-115.1%-143.2%+51.3%
Margin %-179.9%-122.7%-574.9%-4671.1%-72.8%
EV / EBIT-16.3x-11.0x-14.1x-6.4x-19.0x
Net Income$-49.8M$-58.7M$-113.0M$-274.5M$-113.7M
YoY %-44.3%-17.9%-92.6%-143.0%+58.6%
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (GAAP)-$1.41-$1.42-$1.96-$3.36-$1.28
YoY %-0.7%-0.7%-38.0%-71.4%+61.9%